electrochemical synthesis of 5-aminosalicylic acid from 5- nitrosalicylic acid in alkaline media

Electrochemical Synthesis of 5-Aminosalicylic Acid from 5- Nitrosalicylic Acid in Alkaline Media

5-Aminosalicylic acid (5-ASA) is currently prepared by electrochemical reduction of 5-nitrosalicylic acid (5-NSA) in acidic media. In this work, electrolytic reduction of 5-NSA in alkaline media is presented. Reactionconditions and parameters such as anode and cathode electrodes, electrolyte type, reaction time, temperature,current, and the pH for isolation of product are investigated. The yiel...

Nephrotoxic lesions from 5-aminosalicylic Acid.

5-Aminosalicylic acid given to rats as a single intravenous injection led to necrosis of the proximal convoluted tubules and of the renal papilla. These two lesions developed at the same time and the cortical lesions did not appear to be a consequence of the renal papillary necrosis. Since the compound possesses the molecular structure both of a phenacetin derivative and of a salicylate these o...

Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis

Objective(s): This study is aimed to design and synthesize a prodrug of 5-aminosalicylic acid and evaluate its ameliorative effect on experimental ulcerative colitis (UC).Materials and Methods: 5-Aminosalicylic acid-alanine (5-ASA-ALA) was synthesized and characterized. Its stability study was conducted in rat plasma and in the gastroint...

Mesalazine (5-aminosalicylic acid) induced chronic hepatitis.

BACKGROUND Treatment of ulcerative colitis or Crohn's disease with sulphasalazine causes several adverse effects, including hepatitis. Sulphasalazine is cleaved by colonic bacteria into 5-aminosalicylic acid and sulphapyridine. Received wisdom was that 5-aminosalicylic acid was topically active, whereas sulphapyridine was absorbed and caused immunoallergic side effects. Mesalazine, a slow relea...

aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion

What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

Sulphasalazine was developed in the 1930s, initially for use in patients with rheumatic polyarthritis. However, its modest eVects in arthritis were soon overshadowed by the striking benefits seen when the drug was given to patients with active colitis. Controlled clinical trials confirmed the early favourable impressions and established a role for sulphasalazine in the treatment of active disea...